Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Selincro

- PMLiVE

Cancer Drugs Fund “may have harmed patients”

Researchers claim most CDF drugs failed to show benefits to patients

National Institute for Health and Care Excellence NICE logo

NICE turns down Opdivo for head and neck cancer

BMS’s nivolumab proves too costly for the NHS

- PMLiVE

Focus on value: A prescription for pharma

The pricing debate demands a common language to be developed

- PMLiVE

Snapchat arrives at scientific meetings

And NICE becomes the first public health body to use the platform

National Institute for Health and Care Excellence NICE logo

NICE knocks-back Shire’s pancreatic cancer drug Onivyde

Final guidance rules it's not a cost-effective use of NHS resources

Biogen Idec building

NICE backtracks on Biogen’s multiple sclerosis drug Zinbryta

Recommends the treatment after new cost effectiveness and a discount provided

National Institute for Health and Care Excellence NICE logo

NICE agrees £20m cost ceiling for new drugs

New budget test set to begin from April and could delay uptake of new medicines

- PMLiVE

NICE set to back Parsabiv for kidney disease complication

Draft guidance recommends Amgen treatment for secondary hyperparathyroidism

- PMLiVE

NICE turns down first-line Keytruda for lung cancer

High cost of drug puts it above cost-effectiveness threshold

National Institute for Health and Care Excellence NICE logo

Amicus gets NICE green light for Fabry drug

Oral therapy alternative Galafold approved for routine NHS use

- PMLiVE

Lighting the way

How the UK’s Accelerated Access Review aims to guide medical innovations to their destination

- PMLiVE

NICE blocks second Alexion rare disease drug in a week

Says high cost and “considerable uncertainties” over long-term benefits prohibit routine NHS use

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links